Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

Everyone now knows these PR's are to pump up the stock so that the toxic lender can continue to sell the stock.

Plagens didn't generate meaningful sales, Magniant hasn't generated significant sales, their new VP of Sales will likely not generate significant sales because the device itself lacks medical reimbursement and the required large well-controlled studies necessary to get it.

Still going sub-penny unless management buy-out the notes or announces millions in revenue, neither of which are remotely possible right now.

This is a better technology for opioid avoidance after surgery:

Avanos - The truth shouldn't hurt

Note that On-Q has shown a reduction in the use of opioids after surgery in 44 clinical trials (44!) in a wide array of surgical procedures. ENDV has only a couple of small pilot trials which is why they have no sales and Avanos did more than $650 million in sales last year.